Navigation Links
Nutrition 21 to Report Third Quarter Fiscal 2008 Financial Results Thursday, May 8, 2008
Date:4/25/2008

PURCHASE, N.Y., April 25 /PRNewswire-FirstCall/ -- Nutrition 21, Inc. (Nasdaq: NXXI), a growing developer and marketer of nutritional supplements under the Chromax(R), Diabetes Essentials(TM) and Iceland Health(R) brands that help consumers manage blood sugar levels, improve cardiovascular health, enhance memory, and address chronic joint pain, will report financial results prior to the market open on Thursday, May 8, 2008 for the third quarter of fiscal year 2008, ended March 31, 2008. The Company has scheduled a conference call to review the results of the quarter that same day (Thursday, May 8, 2008) at 8:30 AM ET.

Participants can dial (866) 562-9910 or (706) 679-5064 to access the conference call, or can listen via a live Internet web cast, which can be found at http://www.nutrition21.com. A replay of the call is available by visiting http://www.nutrition21.com for the next 30 days or by calling (800) 642-1687 or (706) 645-9291, access code 43095471, through May 11, 2008.

About Nutrition 21

Nutrition 21, Inc. (NASDAQ: NXXI), headquartered in Purchase, NY, is a nutritional supplement company and the maker of chromium picolinate-based and omega-3 fish oil-based supplements with health benefits substantiated by clinical research. Nutrition 21 holds more than 30 patents for nutrition products and uses. Nutrition 21's portfolio of health and wellness brands include: Chromax(R), Core4Life(T
'/>"/>

SOURCE Nutrition 21, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Video: Nutrition Comes to NASCAR
2. Fitness Champion Natalie Waples to be Spokesperson for Natural Nutrition International Direct Marketing Campaign
3. Cities Say Restaurant Nutrition Information Crucial in Fighting Obesity
4. FDA: Use the Nutrition Facts Label to Make Healthy Food Choices
5. Vitamin Relief Brings Needed Nutrition to School District Resurrecting After Katrina
6. Vatican Affirms Church Teaching on Nutrition and Hydration for Individuals In Vegetative State
7. Comment Regarding Congregation for the Doctrine of Faith Clarification Concerning Nutrition and Hydration for Patients in a Persistent Vegetative State
8. The Nutrition-Conscious Are Taking a Bite Out of Fast Food
9. The Nutrition-Conscious Take a Bite Out of Fast Food
10. Wellcorps International Unveils New Nutritional Supplements
11. Nutrition model stresses positive experience of eating
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...quick to condemn hurtful comments, study suggests ...- Many people overestimate how strongly they would... , Sixty-three percent of study participants at...er for an experiment with a white person rather th...acist comments about the black person when he left...
(Date:1/8/2009)..., Md., Jan. 8 Hanger Or...announce that throughout the fourth quarter of 200... Center, Rocky Mountain Orthotic-Prosthetics Cente...nc., First Coast Orthotics & Prosthetics, and ...uisitions add patient care centers to existing mar...
(Date:1/8/2009)...ESDA, Md., Jan. 8 /PRNewswire-Asia/ -- Chindex Int...e Company"), a leading independent American,provi... the People,s Republic,of China, today announced ...,China Conference, to be held in Shanghai on Janua...ina Conference will be held at the Pudong Shangri-...
(Date:1/8/2009)...Pa., Jan. 8 Cephalon, I...Baldino, Jr., Ph.D., Chairman and CEO will presen...held on January 13, 2009 in San Francisco, CA at a...n Time). The presentation will be webcast live on ...bsite. , , The webcast will be archived for on...
Breaking Medicine News(10 mins):Health News:Many Turn Blind Eye to Racism 2Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2Health News:Chindex International Inc. Announces Participation in the 2009 UBS Greater China Conference 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 3
...f the major causes of death among South Africa's y...s said. // Head of Policy Co-ordination and Advis...nzhe said they had conducted research and found th...e in HIV-AIDS-related deaths among young South Afr...
...complex mouth movements like blowing bubbles and l...age quickly, researchers say. // Katie Alcock and...tain studied 120 toddlers and carried out a series...s that might predict a child's ability to develop ...
...t transplants are on the decline. This is because ...y//. Hence the doctors at the Papworth Hospital in...rt was kept beating for five hours after it was re...n to receive a beating heart transplant was Michae...
...y of Adrian Bird, a molecular geneticist at the Un...23rd June// that the abnormally high levels of a p...s models of Rett Syndrome is causing its mitochond...rk overtime. Dr. Bird stated that this is the firs...
Other Medicine News:Health News:Latest In the Heart Transplant Field 2Health News:Researchers Have Linked Rett Syndrome to Mitochondrial Gene 2Health News:Researchers Have Linked Rett Syndrome to Mitochondrial Gene 3
(Date:1/8/2009)...o, Jan. 8 IntelligentMDx a develope...ays, today announced that verification studies of ... complete. , , Under the verification protocol...d reproducibility and robustness of the BK Viral Q... agreed with internally generated analytical perfo...
(Date:1/7/2009)...re-FirstCall/ -- Eli Lilly and Company,(NYSE: L...esponse letter from,the U.S. Food and Drug Admini...on (LAI) for acute and maintenance treatment of sc...k with the agency on the new drug,application (ND...al clinical trials for the continued,review of th...
(Date:1/7/2009)...rease , , WHITE PLAINS, N.Y., Jan. 7 /PRNewswir... that the decades-long rise in the United States p...than ever at increased risk of death and disabilit...43,000 babies were born too soon in 2006, accordin...ich today released "Births: Final data for 2006," ...
(Date:1/7/2009)...opment Based On Osteotech,s Proprietary Human Coll...on; FDA Filing Anticipated in Third Quarter 2009 ...ll/ -- Osteotech, Inc. (Nasdaq: OSTE ), a lead...regenerative healing, announced today that it has ...h(TM) BioRegeneration Matrix. The first five patie...
Breaking Medicine Technology:Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed 2Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 4FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 5FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 6Preterm Births Rise 36 Percent Since Early 1980s 2Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 2Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 3MINRAD International Inc Announces FDA Approval of Petrem 28TM 29 Sevoflurane 21372 1MINRAD International Inc Announces FDA Approval of Petrem 28TM 29 Sevoflurane 21372 2Congressional Leaders and Mens Health Network Emphasize the Importance of Health During the 15th Annual National Mens Health Week 21370 1Congressional Leaders and Mens Health Network Emphasize the Importance of Health During the 15th Annual National Mens Health Week 21370 2Consumer Reports 3A Patients Overdose on Debt As Lenders Doctors and Hospitals Push Risky Credit to Pay for Medical Care 21368 1Consumer Reports 3A Patients Overdose on Debt As Lenders Doctors and Hospitals Push Risky Credit to Pay for Medical Care 21368 2Consumer Reports 3A Patients Overdose on Debt As Lenders Doctors and Hospitals Push Risky Credit to Pay for Medical Care 21368 3Consumer Reports 3A Patients Overdose on Debt As Lenders Doctors and Hospitals Push Risky Credit to Pay for Medical Care 21368 4Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 1Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 2Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 3Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 4Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 5Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 6Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 7
...ently approved by FDA for long-term maintenance,tr...ate first,nebulized formoterol fumarate provides i...moterol, enhanced patient quality of,life, and pos...7 /PRNewswire/ -- Data presented at the,Internatio...TS),demonstrate that Perforomist (formoterol fumar...
...ivolol Lowers Blood Pressure in Obese and,Non-Obes...Newswire-FirstCall/ -- Forest,Laboratories, Inc. t...dies and one pooled analysis of nebivolol, a selec...urrently under review by,the U.S. Food and Drug Ad...on. Data from the two clinical studies show that,n...
Other Medicine Technology:Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 2Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 3Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 4
Durable ergonomic chairs with concave seats and large backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • Choose the BE Series for top
Durable ergonomic chairs with concave seats and large backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • Choose the BE Series for top
Durable ergonomic chairs with concave seats and large backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • Choose the BE Series for top
Durable ergonomic chairs with concave seats and large backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • Choose the BE Series for top
Medicine Products: